Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clinical Research Platform Into Molecular Testing, Treatment and Outcome of (Non-)Small Cell Lung Carcinoma Patients

Trial Profile

Clinical Research Platform Into Molecular Testing, Treatment and Outcome of (Non-)Small Cell Lung Carcinoma Patients

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 04 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Afatinib (Primary) ; Carboplatin (Primary) ; Cisplatin (Primary) ; Crizotinib (Primary) ; Erlotinib (Primary) ; Gefitinib (Primary) ; Gemcitabine (Primary) ; Pembrolizumab (Primary) ; Pemetrexed (Primary) ; Taxanes (Primary)
  • Indications Carcinoma; Non-small cell lung cancer; Small cell lung cancer; Squamous cell cancer
  • Focus Adverse reactions; Biomarker; Pharmacodynamics; Therapeutic Use
  • Acronyms CRISP
  • Most Recent Events

    • 29 Oct 2019 Planned End Date changed from 1 Dec 2022 to 1 Dec 2025.
    • 29 Oct 2019 Planned primary completion date changed from 1 Sep 2021 to 1 Sep 2023.
    • 05 Jun 2018 Results (n=823) presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top